Intraventricular injections of tachykinin NK3 receptor agonists suppress the intake of "salty" tastes by sodium deficient rats.
Intraventricular injections of the tachykinin NK3 receptor (NK3-R) agonist, senktide, suppress the ingestion of hypertonic (0.5 M) NaCl by decreasing the initial lick rate and accelerating the decay in lick rate in sodium deficient rats. The present experiment examined whether the effects of intraventricular injections of senktide on lick rate were selective for NaCl solution, or if the ability of NK3-R agonists to inhibit intake generalizes other sodium-containing solutions. The effects of lateral ventricular injections of isotonic saline or senktide (200 ng) on intake and lick rate of 0.5 M solutions of sodium chloride (NaCl), sodium acetate (Na acetate), sodium bicarbonate (Na bicarbonate), and monosodium glutamate (MSG) were measured in sodium deficient rats. Compared to saline injection, senktide injection had no effect on the lick rate or intake of Na bicarbonate. In contrast, intraventricular injection of senktide suppressed the intake of NaCl, Na acetate, and MSG compared to saline injection. Senktide injection accelerated the decay in lick rate for NaCl, Na acetate and MSG, but only suppressed the initial lick rate for NaCl and Na acetate. The results show that activation of NK3-R in sodium deficient rats suppresses the intake of tastes that are classified as "salty" tasting and that the decrease in intake reflects effects on the initial lick rate, the decay in lick rate, or both.
Flynn
Francis W
FW
Department of Zoology and Physiology, Graduate Neuroscience Program, University of Wyoming, Laramie, WY 82071, USA. Flynn@uwyo.edu
D000818:Animals; D001522:Behavior, Animal; D004327:Drinking Behavior / Q000187:drug effects; D004435:Eating / Q000187:drug effects*; D007276:Injections, Intraventricular / Q000379:methods; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects; D018042:Receptors, Neurokinin-3 / Q000819:agonists* / Q000502:physiology; D012462:Saline Solution, Hypertonic / Q000378:metabolism; D012964:Sodium / Q000172:deficiency*; D019346:Sodium Acetate / Q000378:metabolism; D017693:Sodium Bicarbonate / Q000378:metabolism; D012970:Sodium Glutamate / Q000378:metabolism; D013373:Substance P / Q000031:analogs & derivatives* / Q000494:pharmacology; D013649:Taste / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology
D010446:Peptide Fragments; D018042:Receptors, Neurokinin-3; D012462:Saline Solution, Hypertonic; C054724:senktide; D013373:Substance P; D019346:Sodium Acetate; D017693:Sodium Bicarbonate; D012964:Sodium; D012970:Sodium Glutamate